Global Human Growth Hormone Market growing at a CAGR of 8.2% from 2023 to 2030
Category : Healthcare | Published Date : Jun 2023 | Type : Press Release
Key Market Overview
The global human growth hormone market is expected to grow at a significant growth rate during the forecast period of 2023-2030. The Consegic Business Intelligence analyzes that the global human growth hormone market is expected to reach USD 9,267.74 million in 2030, which was USD 4,946.64 million in 2022, and register a compound annual growth rate of 8.2%.
The report highlights the increasing demand for human growth hormone due to rising cases of Growth Hormone Deficiency. Consegic Business Intelligence study also provides insights into the market's competitive landscape, market segmentation, regional outlook, and emerging technologies in the human growth hormone market.
Global Human Growth Hormone Market By Overview
The human growth hormone market is bifurcated into the route of administration, application, and distribution channel. Based on the route of administration, the market is segmented into subcutaneous, oral, intramuscular, intravenous, and others. In 2022, the subcutaneous segment accounted for the highest market share in the human growth hormone market. The application segment is categorized into Growth Hormone Deficiency, Prader-Willi Syndrome, Idiopathic Short Stature, Turner Syndrome, and Others. In 2022, the Growth Hormone Deficiency segment accounted for the highest market share in the human growth hormone market. Based on distribution channel, the market is segmented into hospitals, retail pharmacies, online pharmacies, and others. In 2022, the hospital segment accounted for the highest market share in the human growth hormone market.
Get Free SampleMarket Dynamics
Driver:
- Rising incidences of growth hormone deficiency are boosting the demand for the human growth hormone.
Restraints:
- Side effects and other hazards associated with synthetic growth hormone is likely to hamper the market growth.
- The presence of alternative therapy treatments is likely to hamper the market growth.
Market Segmentation:
| Report Attributes | Report Details |
| By Route of Administration | Subcutaneous, Oral, Intramuscular, Intravenous, and Others |
| By Application | Growth Hormone Deficiency, Prader-Willi Syndrome, Idiopathic Short Stature, Turner Syndrome, and Others |
| By Distribution Channel | Hospitals, Retail Pharmacies, Online Pharmacies, and Others |
| By Region | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Competitive Landscape :
The market is dominated by certain major companies such as Novo Nordisk, Merck KGaA, and Eli Lilly & Company have a strong market position in current market circumstances. Further, the human growth hormone market is expected to witness significant growth in the coming years due to the increasing demand for advanced growth hormonal therapy. The market players compete for a firm market position through mergers and acquisitions, product innovations, and business strategies. Thus, evolving research and developments are expected to help market players adopt innovative ways of product creation to cater to the growing needs of various end-use industries.
- Novo Nordisk
- Merck KGaA
- Eli Lilly & Company
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Novartis
- AnkeBio Co., Ltd
- Roche
- Ipsen Biopharmaceuticals, Inc.
- Genentech, Inc.
